Induced Modification And Degradation Of Intracellular Proteins In Lysosomes: Methylarginine Targeting Chimera (MrTAC)

Tech ID: 34129 / UC Case 2024-9AV-0

Brief Description

A revolutionary drug modality for the selective modification and degradation of intracellular proteins in lysosomes.

Full Description

Methylarginine Targeting Chimera (MrTAC) is a heterobifunctional small molecule designed to selectively induce arginine methylation, facilitating the targeted degradation of intracellular proteins within lysosomes. This innovative approach leverages the enzyme protein arginine N-methyltransferase 1 (PRMT1) to chemically modify proteins, directing them towards lysosomal degradation, a pathway previously underutilized in targeted protein degradation therapies.

Suggested uses

  • Targeted cancer therapies by degrading disease-causing proteins overexpressed in cancer cells. 
  • Drug development for diseases associated with protein dysregulation and mutation. 
  • Research tools for studying protein function and methylation effects on cell biology

Advantages

  • High selectivity in targeting specific proteins for degradation without affecting global methylation patterns. 
  • Utilizes the lysosomal degradation pathway, offering an alternative to proteasomal degradation. 
  • Capable of degrading proteins across various cell lines, timescales, and doses. 
  • Drives biological loss-of-function phenotypes affecting survival, transcription, and proliferation. 
  • Overcomes challenges associated with proteasomal targeting, such as ineffective ubiquitination and protein mutation.

Patent Status

Patent Pending

Related Materials

Contact

Learn About UC TechAlerts - Save Searches and receive new technology matches

Other Information

Categorized As


5270 California Avenue / Irvine,CA
92697-7700 / Tel: 949.824.2683
  • Facebook
  • Twitter
  • Twitter
  • Twitter
  • Twitter